Floatz logo

Dapagliflozin

Metabolic Associated Fatty Liver Disease

Post Graduate Institute of Medical Education and Research, ChandigarhSmall moleculePhase 4 / ApprovedActive
BBB
77/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
95/ 100

Competitive context

139 Active assets in the Metabolic Associated Fatty Liver Disease cohort.

Asset / SponsorPhaseRating
Empagliflozin
Justin Ryder
Phase 4BBB
Exenatide
Fudan University
Phase 4BBB
Metformin
Xiqiao Zhou
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB
Tirzepatide
Regeneron Pharmaceuticals
Phase 3BBB

View all 50 →

Same molecule, other indications

Dapagliflozin is also rated in:

type 2 diabetes mellitusDormant
BBB
Indicative ·
78 / 100
View asset →
arteriosclerosis disorderDormant
BBB
Indicative ·
73 / 100
View asset →
diabetes mellitusDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →